Yescarta
Payments companies reported to CMS as associated with Yescarta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Yescarta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Yescarta
These are the largest totals companies reported as associated with Yescarta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Marco Davila | Buffalo, NY | Medical Oncology | $142,076.14 |
| Ariel Perez Perez | Miami, FL | Hematology & Oncology | $111,506.50 |
| Olalekan Oluwole | Nashville, TN | Hematology & Oncology | $105,127.48 |
| Usama Gergis | Allentown, PA | Hematology & Oncology | $102,862.77 |
| Ahmed Galal | Morristown, NJ | Hematology (Internal Medicine) | $96,867.67 |
| Raghuveer Ranganathan | Los Angeles, CA | Hematology & Oncology | $78,522.11 |
| Rushang Patel | Orlando, FL | Medical Oncology | $72,582.44 |
| Ran Reshef | New York, NY | Hematology (Internal Medicine) | $70,797.53 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $67,083.90 |
| Yi Lin | Rochester, MN | Hematology (Internal Medicine) | $61,188.63 |
Prescribed Yescarta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.